reduced by the use of drug-coated balloons. However, dose, coating composition, and technology are decisive for efficacy.
Objectives: Ultrasmall superparamagnetic particles of iron oxide (USPIO) detect cellular inflammation and tissue-resident macrophages on magnetic resonance imaging (MRI). In patients with abdominal aortic aneurysm (AAA), we assessed whether USPIO-enhanced MRI can predict AAA growth and clinical outcomes.
Methods: In a prospective multicenter open-label imaging cohort study, we recruited 361 patients with AAA (diameter $40 mm) who underwent baseline USPIO-enhanced MRI. Patients were classified according to the presence of USPIO uptake in the wall of the AAA. All participants were monitored with serial ultrasound imaging and clinical follow-up for a minimum of 2 years. The primary end point was the composite of AAA rupture or repair.
Results: During baseline assessment, 19 patients were withdrawn by the attending clinician or at the participant's request. The study population of 342 participants were predominantly male (293 [85%]), with a mean age of 73 6 7 years and AAA diameter of 50 6 8 mm. Mural USPIO uptake was indeterminate in five participants. During a mean follow-up of 1006 6 279 days, there were 17 (5.0%) AAA ruptures, 126 (36.8%) AAA repairs, and 48 (14.0%) deaths. Compared to those without uptake, patients with mural USPIO uptake had increased AAA expansion (3.4 6 2.4 vs 2.5 6 2.4 mm/y; difference, 0.8 mm/y; 95% confidence intervals [CI] 0.22-1.39 mm/y; P ¼ .007) and higher rates of AAA rupture or repair (69 of Objectives: Endovenous laser ablation (EVLA) is a recommended first-line treatment for superficial venous incompetence (SVI). However such thermal technique requires tumescent anesthesia, which can be uncomfortable for the patient. Newer nonthermal techniques, such as mechanochemical ablation (MOCA), aim to remove or reduce the need for tumescent and thus reduce pain. This randomized controlled trial compared the two treatments with 6 months' follow-up.
Methods: Patients undergoing ablation for symptomatic primary unilateral SVI were randomized to EVLA or MOCA. Concomitant phlebectomy was performed on symptomatic visible varicosities. Outcomes included intraprocedural and postprocedural pain scores on a 100-mm visual analog scale, clinical severity scores, quality of life measurements, recovery time, and duplex ultrasound assessment. Analysis was performed on an intention-to-treat basis. Data were analyzed using parametric and nonparametric statistical tests as dictated by the distribution of data.
Results: Eighty-two patients were randomized (41 MOCA and 41 EVLA). The mean age was 53 years, and 59% were female. Both groups were well matched at baseline. Patients in the MOCA group experienced significantly less pain during truncal ablation (MOCA median 10 mm (interquartile range, 9-24 mm) vs EVLA median 28 mm (interquartile range, 19-59 mm; P ¼ .01). However this benefit was lost following concomitant phlebectomy, and there was no significant difference in the overall pain scores by the end of the procedure (P ¼ .441). Patients in the MOCA group also experienced less pain during the next six postprocedural days (by 5 to 14 mm; P < .05). There was no significant difference between the groups for either return to work (MOCA: median 7 days [interquartile range, 4-14 days] vs EVLA: median, 6 days [interquartile range, 4-14 days]; P ¼ .812) or return to normal activities (MOCA: median 2 days [interquartile range 1-3 days] vs EVLA: median 3 days [interquartile range 1-7 days]; P ¼ .169). Technical success (MOCA: 92% vs EVLA: 94%), clinical severity scores, and disease-specific quality of life scores were similar between groups at 6 weeks and 6 months. There were no significant complications.
Conclusions: During truncal ablation, MOCA is less painful than EVLA, but this benefit is lost if concomitant phlebectomy is performed. MOCA appears less painful during the first postprocedural week. Both have similar recovery time, clinical improvement, short-term technical success, quality of life improvement, and safety outcomes. Longer follow-up is required.
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